Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 8, 2014, Pages 946-951

  Abate, Dereje ^a,b   Tedla, Y ^b   Meressa, D ^b,c   Ameni, G ^a  

^a ADDIS ABABA UNIVERSITY   (Ethiopia)

^b St Peter TB Hospital   (Ethiopia)

^c Global Health Committee   (Ethiopia)

Author keywords

Ethionamide; InhA; KatG; Multidrug resistant tuberculosis; RpoB

Indexed keywords

ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT; CODON; ETHIONAMIDE;

ADULT; ARTICLE; CODON; CONTROLLED STUDY; ETHIOPIA; FEMALE; GENE; GENE MUTATION; HUMAN; KATG GENE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; PROMOTER REGION; RETROSPECTIVE STUDY; RPOB GENE; TREATMENT OUTCOME; TUBERCULOSIS; ADOLESCENT; AGED; CHILD; DOSE RESPONSE; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MUTATION; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CODON; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHIONAMIDE; ETHIOPIA; FEMALE; HUMANS; ISONIAZID; MALE; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84904580872     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0926     Document Type: Article

References (29)

1. World Health Organization. Global tuberculosis report, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
2. World Health Organization. Treatment of tuberculosis guidelines. 4 th ed. WHO/HTM/TB/2009.420. Geneva, Switzerland: WHO, 2010.
3. Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull G, Jacobs W R, ed. Molecular genetics of mycobacteria. Washington DC, USA: ASM Press, 2000: pp 235-254.
4. Telenti A, Imbode F, Marchesi D, et al. Detection of rifampicin resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-650. (Pubitemid 23083244)
5. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
6. Zhang Y, Jacobs R. Mechanisms of drug resistance in Mycobacterium tuberculosis. In: S.T.C. et al., ed. Tuberculosis and the tubercle bacillus. Washington DC, USA: ASM Press, 2000: pp 115-140.
7. Riska P, Jacobs J, Alland D. Molecular determinants of drug resistance in tuberculosis. Int J Tuberc Lung Dis 2000; 4: 4-10.
8. Mokrousov I, Narvskaya O, Otten T, et al. High prevalence of katG Ser315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob Agents Chemother 2002; 46: 1417-1424. (Pubitemid 34415323)
9. Ongaya V A, Githui WA, Meme H, Kiiyukia C, Juma E. High ethionamide resistance in Mycobacterium tuberculosis strains isolated in Kenya. Afr J Health Sci 2012; 20: 37-41.
10. Tolani M P, Blossom D T D, Mistry N F. Drug resistance mutations and hetero resistance detected using the GenoType®MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India. BMC Infect Dis 2012; 12: 9.
11. Telenti A. Genetics of drug resistant tuberculosis. Thorax 1998; 53: 793-797.
12. Morlock G P, Metchock B, Sikes D, Crawford J T, Cooksey R C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47: 3799-3805. (Pubitemid 37484992)
13. Federal Ministry Health of Ethiopia. Control and management of drug-resistant tuberculosis: clinician's pocket book. Addis Ababa, Ethiopia: FMOH, 2010.
14. Guo H, Seet Q, Denkin S, Parsons L, Ying Z. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006; 55: 1527-1531. (Pubitemid 44713868)
15. Abate G, Miorner H, Ahmed O, Hoffner S E. Drug resistance in Mycobacterium tuberculosis strains isolated from retreatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Int J Tuberc Lung Dis 1998; 2: 580-584. (Pubitemid 28320067)
16. World Health Organization/International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Fourth Global Report. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
17. Abate D, Taye B, Abseno M, Biadgilign S. Epidemiology of anti-tuberculosis drug resistance patterns and trends in tuberculosis referral hospital in Addis Ababa, Ethiopia. BMC Res Notes 2012; 5: 462.
18. Zhang Y, Yew W-W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1320-1330.
19. Ramaswamy S V, Musser J M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Int J Tuberc Lung Dis 1998; 79: 3-29. (Pubitemid 29050434)
20. Caws M, Duy P M, Tho D Q, Lan N T N, Hoa D V, Farrar J. Mutations prevalent among rifampin and isoniazid resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J Clin Microbiol 2006; 44: 2333-2337. (Pubitemid 44092394)
21. Miotto P, Piana F, Penati V, Canducci F, Migliori G B, Cirillo D M. Use of GenoType®MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J Clin Microbiol 2006; 44: 2485-2491. (Pubitemid 44092416)
22. Tessema B, Beer J, Emmrich F, Sack U, Rodloff A C. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia. BMC Infect Dis 2012; 12: 37.
23. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman M E. Rapid molecular screening for multidrug resistant tuberculosis in a high volume public health laboratory in South Africa. Am J Respir Dis Crit Care Med 2008; 177: 787-792. (Pubitemid 351490566)
24. Barnard M, Parsons L, Miotto P, Cirillo D, Feldmann K, Gutierrez C, Somokovi A. Molecular detection of drug resistant tuberculosis by line-probe assay: laboratory manual for resource limited settings. Geneva, Switzerland: Foundation for Innovative New Diagnostics, 2012.
25. World Health Organization. Molecular line-probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis. Expert Group Report. Geneva, Switzerland: WHO, 2008.
26. Gillespie S H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002; 46: 267-274. (Pubitemid 34087167)
27. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Performance of the GenoType®MTBDR line-probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol 2006; 44: 3659-3664. (Pubitemid 46768798)
28. Schaaf H S, Victor T C, Venter A, et al. Ethionamide cross- and co-resistance in children with isoniazid resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1355-1359.
29. World Health Organization. Guidelines for the programatic management of drug resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.